Mass Tort brief
California Supreme Court Shields Gilead as Major Mass Torts Settle and Expand
California's high court rejects a 'duty to innovate' while Pfizer, Sandoz, and TikTok resolve major legal overhangs.
Mass Tort
California's Supreme Court shut down a $24 billion lawsuit against Gilead — rejecting a 'duty to innovate' theory that threatened to penalize drug makers for launch timing.
BackgroundOver 24,000 plaintiffs claimed Gilead intentionally delayed commercializing a safer HIV medication to maximize revenue from older treatments. Lower courts allowed negligence claims to proceed, creating a threat that manufacturers could face tort liability for drug release timing.
- The 6-1 decision shuts down a novel legal theory that threatened to penalize pharmaceutical companies for delaying new product launches, protecting corporate research and development decisions.
- Justices directed summary judgment for Gilead, completely ending product liability claims for non-defective medications that were allegedly held back from market release.
- Legal experts warned that upholding lower court rulings would have exposed tech and pharma companies to constant litigation over product update schedules, preserving commercial innovation timelines.
Mass Tort
Sandoz agreed to a $450 million settlement to resolve generic price-fixing claims — clearing legacy Novartis liabilities as multidistrict trials continue against peers.
BackgroundState attorneys general filed antitrust lawsuits accusing generic drug manufacturers of colluding to fix prices and divide markets for dozens of medicines. Sandoz spun off from Novartis as an independent generic drug producer in 2023 while inheriting legacy litigation exposure.
- Sandoz will pay $400 million to 43 states over seven years alongside $28.5 million to indirect reseller classes, resolving state-level antitrust claims.
- The settlement includes no admission of wrongdoing, removing long-standing litigation uncertainty that hung over Sandoz since its corporate spin-off.
- Multidistrict antitrust litigation in Pennsylvania continues against remaining generic manufacturers, maintaining legal pressure across the broader generic industry.
Mass Tort
TikTok settled its first teen addiction trials in secret — buying exit from a California courtroom while Meta, Google, and Snap face an October jury trial.
BackgroundOver 3,300 youth mental health lawsuits are consolidated in California state court, accusing social media platforms of engineering addictive design features that harm children. Bellwether trials test jury reactions to establish settlement valuation benchmarks across the broader litigation.
- TikTok settled three representative bellwether trials confidentially before jury selection began, avoiding public disclosures about platform algorithm risks.
- Claims against Meta, Alphabet, and Snap remain active and scheduled for an October consolidated trial, keeping broad tech industry liability intact.
- An earlier March jury verdict awarded $6 million against Meta and Google in a separate California bellwether, raising settlement price tags across pending cases.
Mass Tort
Jury deliberations began in the first Covidien hernia mesh trial — testing internal document evidence that will dictate settlement values for 2,400 pending injury claims.
BackgroundHernia mesh litigation consolidates thousands of personal injury lawsuits claiming synthetic mesh products degrade inside patients, causing severe internal injuries and revisions. Covidien operates as a surgical device subsidiary of Medtronic.
- Plaintiffs presented internal testing showing collagen barrier breakdown in seven days despite marketing claims of a month, alleging deception of treating surgeons.
- The initial jury verdict will establish baseline settlement values across 2,400 active federal lawsuits, driving negotiations for global resolution terms.
- A second federal bellwether trial against Covidien is currently underway in Boston, maintaining pressure on Medtronic to resolve the litigation.
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.